Bleeding Risk: Using DAPT Score to Minimize Complications While Maintaining Efficacy
Christopher Cannon, Editor in Chief, Harvard Health Publishing, shared a post on LinkedIn:
“A prospective randomized trial using the DAPT Risk score to tailor duration of DAPT – showing benefit in reducing bleeding and overall net benefit!!! I have been using the DAPT Risk score developed by Robert Yeh and Laura Mauri, but this is the first validation.
In the personalized DAPT duration arm, DAPT duration was 3 months for patients with low DAPT score and chronic coronary syndrome, 6 months for patients with low DAPT score and acute coronary syndrome, or 24 months for patients with high DAPT score (irrespective of the clinical presentation).
In the control arm, DAPT duration was 12 months”
Read full article here.
Title: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation
Authors: Raffaele Piccolo, Paolo Calabrò, Greta Carrara, Fiorenzo Simonetti, Attilio Varricchio, Tiziana Attisano, Giovanni Napolitano, Ciro De Simone, Gerardo Carpinella, Eugenio Stabile, Plinio Cirillo, Luigi Di Serafino, Gianluca Caiazzo, Tullio Tesorio, Marco Boccalatte, Bernardino Tuccillo, Marisa Avvedimento, Attilio Leone, Gennaro Galasso, Arturo Cesaro, Rocco Perrotta, Tullio Niglio, Domenico Simone Castiello, Maddalena Immobile Molaro, Luca Bardi, Alessandra Spinelli, Stefano Cristiano, Michele Bellino, Sergio Leonardi, Simone Biscaglia, Francesco Costa, Salvatore Cassese, Eugene McFadden, Dik Heg, Giulio G. Stefanini, Anna Franzone, Davide Capodanno, Giovanni Esposito
Stay updated with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals